Ken Fisher
MRNA icon

Ken Fisher’s Moderna MRNA Stock Holding History

Ken Fisher’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,265
Closed -$419K – 998
2024
Q3 		$419K Buy
+6,265
New +$575K ﹤0.01% 781
2024
Q1 		– Sell
-2,067
Closed -$206K – 1019
2023
Q4 		$206K Buy
+2,067
New +$174K ﹤0.01% 950
2023
Q1 		– Sell
-1,638
Closed -$294K – 1161
2022
Q4 		$294K Buy
+1,638
New +$268K ﹤0.01% 918
2022
Q3 		– Sell
-2,136
Closed -$305K – 979
2022
Q2 		$305K Sell
2,136
-64
-3% -$9.15K ﹤0.01% 791
2022
Q1 		$379K Sell
2,200
-385
-15% -$64.8K ﹤0.01% 777
2021
Q4 		$657K Buy
2,585
+319
+14% +$93.3K ﹤0.01% 710
2021
Q3 		$872K Sell
2,266
-697
-24% -$257K ﹤0.01% 642
2021
Q2 		$696K Buy
2,963
+1,371
+86% +$245K ﹤0.01% 668
2021
Q1 		$208K Sell
1,592
-335
-17% -$48.5K ﹤0.01% 855
2020
Q4 		$201K Buy
+1,927
New +$195K ﹤0.01% 878

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Ken Fisher's MRNA Position: Q4 2024 in Review

Ken Fisher sold out of Moderna (MRNA) in Q4 2024, closing a stake of 6,265 shares — an estimated $419K sold.

Ken Fisher first reported a position in MRNA in Q4 2020 and held it in 10 quarters. The position peaked at $872K in Q3 2021. 746 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Ken Fisher reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Ken Fisher sold 6,265 Moderna shares in Q4 2024, an estimated $419K.
  • Ken Fisher first reported a position in Moderna in Q4 2020 and held it in 10 quarters.
  • Ken Fisher's Moderna position peaked at $872K in Q3 2021.
  • 746 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Fisher Asset Management's 13F filing for Q4 2024, filed 5 Feb 2025.